← Back to patent-cliff list
RAY-1225
Tier C — Watch / tradeRAY-1225
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GIPR
Indications (approved)：Type 2 diabetes, Overweight, Obesity, Obstructive sleep apnoea syndrome, Non-alcoholic steatohepatitis, 急性肾损伤, Hepatic function decline
Regional status
US
-
EU
-
China
Phase III
2025-06-19
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RAY-1225?
Approved indications include: Type 2 diabetes, Overweight, Obesity, Obstructive sleep apnoea syndrome, Non-alcoholic steatohepatitis, 急性肾损伤, Hepatic function decline.
When does the RAY-1225 patent expire?
No public expiry year is available for RAY-1225 yet; this page updates once verified.
How do I get a quote for RAY-1225 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30